Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.

J Infect Dis. 1999 Mar;179(3):576-83. Unique Identifier : AIDSLINE MED/99137792
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Schutzbank T; Spector SA; Baker CJ; Englund JA; Department of Pediatrics, University of Medicine and Dentistry of; New Jersey, Newark, NJ 07103, USA. palumbo@umdnj.edu

Abstract: Plasma human immunodeficiency virus RNA and CD4 lymphocyte response to nucleoside reverse-transcriptase therapy were evaluated in a large, comparative pediatric trial. Both baseline values and changes in the two laboratory markers over time correlated well with clinical outcome and possessed independent predictive value. In comparison of RNA reduction from baseline between the dideoxyinosine (ddI) and zidovudine+ddI therapeutic arms, marginal superiority of the combination arm was not correlated with an observed clinical benefit. Despite the size of this trial and the significantly higher rate of clinical end points in the zidovudine monotherapy group, attempts to establish surrogacy for plasma RNA were difficult. Nevertheless, plasma RNA and CD4 lymphocyte count together possess strong clinical predictive power and are valuable tools for both the clinician and the evaluation of new therapies.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL Adolescence Anti-HIV Agents/*THERAPEUTIC USE Child Child, Preschool Comparative Study CD4 Lymphocyte Count CD4-Positive T-Lymphocytes/*IMMUNOLOGY Didanosine/*THERAPEUTIC USE Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY/VIROLOGY HIV-1 Reverse Transcriptase/ANTAGONISTS & INHIB Infant Reverse Transcriptase Inhibitors/*THERAPEUTIC USE RNA, Viral/*BLOOD Support, U.S. Gov't, P.H.S. Time Factors Zidovudine/*THERAPEUTIC USE
990630
A9960915

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .